173 related articles for article (PubMed ID: 38637883)
1. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
3. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.
Huang N; Feng Y; Liu Y; Zhang Y; Liu L; Zhang B; Zhang T; Su Z; Xue L; Wu ZB
Int Immunopharmacol; 2024 Apr; 134():112159. PubMed ID: 38692018
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
9. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir.
Covino DA; Desimio MG; Doria M
Sci Rep; 2022 Nov; 12(1):18567. PubMed ID: 36329160
[TBL] [Abstract][Full Text] [Related]
10. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract][Full Text] [Related]
12. Whole exome sequencing reveals novel risk genes of pituitary neuroendocrine tumors.
Peculis R; Rovite V; Megnis K; Balcere I; Breiksa A; Nazarovs J; Stukens J; Konrade I; Sokolovska J; Pirags V; Klovins J
PLoS One; 2022; 17(8):e0265306. PubMed ID: 36026497
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
15. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
Espinoza AF; Patel RH; Patel KR; Badachhape AA; Whitlock R; Srivastava RK; Govindu SR; Duong A; Kona A; Kureti P; Armbruster B; Kats D; Srinivasan RR; Dobrolecki LE; Yu X; Najaf Panah MJ; Zorman B; Sarabia SF; Urbicain M; Major A; Bissig KD; Keller C; Lewis MT; Heczey A; Sumazin P; López-Terrada DH; Woodfield SE; Vasudevan SA
J Hepatol; 2024 Apr; 80(4):610-621. PubMed ID: 38242326
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
Li J; Wen S; Li B; Li N; Zhan X
Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
[TBL] [Abstract][Full Text] [Related]
17. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
18. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
[TBL] [Abstract][Full Text] [Related]
19. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
20. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
